Quality & Accuracy

Experience

The latest technologies

Speed ​​&
Credibility

HPV DNA | Detection & genotyping of high risk types

Known as: HPV DNA | Detection & genotyping of high risk types
SKU: 296

160.00

Research material: urogenital smear
Response time (working days): 1 ****
The test is done on an empty stomach: no
Home call service: No.
Country: EU

General Information

**** Test is done once a week - Friday

Human papillomavirus (HPV) Infection is common in young, sexually active, women under 25 years of age. The average duration of HPV infection is 4-20 months. Within 2 years, 90% of people infected with HPV are "cleansed" of the infection by the immune system. In the remaining 10% - the infection persists, which is associated with an increased risk of developing intraepithelial squamous cell carcinoma. Persistent infection with high-risk HPV genotypes; A prerequisite for the development of cervical cancer and its previous lesions. The presence of oncogenic types of HPV has been shown in almost all cases of cervical cancer.

When should we take the test?

  • Monitoring the development of certain types of HPV infection;
  • Monitoring the resistance of genotypes associated with an increased risk of cervical cancer, especially in patients with negative cytology;
  • Women with ASC-US cytology (atypical squamous cells of unknown origin) and HPV-DNA positive high-risk types;
  • Monitoring the effectiveness of treatment in case of HPV-related cervical injury (conization, radiotherapy or chemotherapy);
  • Pre- and post-vaccination genotyping in selected screening programs;
  • In women 21 years and older with ASC-US (Atypical squamous cells of unknown origin), the test can be used to detect high-risk HPV genotypes - 16, 18 and 45 and to determine the need for colposcopy. This information, along with a physician's screening history assessment, along with other risk factors and professional guidelines, can be used for patient management.
  • In women older than 30 years, The test can be used in conjunction with cervical cytology to screen for high-risk HPV types for additional screening.
  • In women older than 25 years, The test can be used as a first-line screening test for cervical cancer to detect high-risk HPV genotypes, including 16 and 18. Women who test positive for HPV 16 and / or 18 genotypes should have a colposcopy.

The test is not used:

  • To determine the need for treatment in the absence of high-grade cervical dysplasia. Patients who are positive for HPV 16, 18 and 45 should be under constant monitoring because of the risk of developing high-grade cervical dysplasia;
  • For women who have had a hysterectomy;
  • To examine material not collected by the clinic using an endocervical brush / spatula combination (otherwise obtained material is not used for the study).

Possible interpretation of the results

The HPV test has a clinical sensitivity of 93% and a clinical specificity of 87.7%.

  • HPV DNA for 14 high-risk genotypes - Not defined.
  • HPV DNA for 14 high-risk genotypes of HPV In determining Will be reported - genotype or group of genotypes for which a positive result was obtained.

Additional information

Identified More than 120 different types of HPV And about one-third of them can infect genital epithelial cells. They can be classified as follows:

  • Group 1 (carcinogenic types for humans) - HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58 and HPV59
  • Group 2A (most likely to be carcinogenic to humans) - HPV68
  • Group 2B (most likely to be carcinogenic to humans) - HPV26, HPV30, HPV34, HPV53, HPV66, HPV67, HPV 69, HPV70, HPV73, HPV82, HPV85 and HPV97.

between them HPV16 is the most carcinogenic type, which causes 50-60% of cervical cancers while HPV18 Participates in about 10-12% of cases. Thus, 96% of all cases of cervical cancer belong to one of 13 types of HPV (groups 1 and 2A).

Persistence of the virus for 1 year or 2 years, especially HPV16, results in CIN3 (carcinoma-in-situ) - abnormal cells are found in the entire thickness of the cervical surface layer, although the process is not widespread in the deeper layers) or more advanced 3-20% risk of developing lesions (CIN30 +); Untreated CIN3 has a 30% chance of causing invasive cervical cancer within 30 years, while only 3% of untreated CIN1 can become invasive.

Cervical cancer screening The primary goal is to prevent cancer morbidity and mortality. The optimal screening strategy is to identify pre-existing lesions that may progress to invasive cancer and at the same time prevent transient HPV infections.

HPV (human papillomavirus) Screening test, Detects 14 high-risk HPV types: HPV - 16, 18, 31, 45, 51, 52 - types with individual genotypes and other HPV types - from the 2nd or 3rd group of the virus: P1: 33/58; P2: 56/59/66; P3: 35/39/68. The test is based on the determination of HPV DNA by real-time PCR (PCR) research method. Unlike most HPV tests, it allows the genome to replicate regions of the genome that are specific to a particular type of HPV, thus improving the specificity of detection. In addition, by selecting target sequences at the E6 and E7 gene levels, there is no risk of obtaining a false-negative result except in rare cases. Another potential advantage of the test is that enhanced genotyping may lead to a more accurate assessment of the persistence of HPV-specific genotypes in women participating in screening programs and ultimately better stratification of patients according to the degree of risk.

Genotyping of HPV infection allows:

  • Stratification of high-risk patients (HPV 16, 18 or other high-risk HPV types);
  • Detection of multi-infections;
  • Specifying the need for re-treatment due to infection with the same or a new type of HPV;
  • Monitoring the effect after receiving the HPV vaccine;
  • Determine the specific outcome of cytological examination of cervical lesions (e.g. HPV18 and adenocarcinoma).

How to prepare HPV For a DNA test?

Avoid taking samples during menstruation. Also, 48 hours before the sample, patients should avoid sexual intercourse, vaginal douching, intravaginal tampons, topical contraceptives, vaginal gels, creams and medications.

Research material

Both tests are performed using a single study material.

  • Cells from exocervical, endocervical, and transitional regions (transformation zone) are required for the study.
  • The study material should be taken by a professional.

0/5 (0 Reviews)

Testing process

Purchase a test Submission of material

Purchase a test

Submission of material

Results Online Consult a doctor

Results Online

Consult a doctor

Laboratories
English EN Georgian KA Russian RU
Call Now Button